172 related articles for article (PubMed ID: 26137524)
1. mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?
Kwiatkowski DJ; Wagle N
EBioMedicine; 2015 Jan; 2(1):2-4. PubMed ID: 26137524
[No Abstract] [Full Text] [Related]
2. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
3. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of mTOR in aging and cancer.
Zhavoronkov A
Oncotarget; 2015 Dec; 6(42):45010-1. PubMed ID: 26942715
[No Abstract] [Full Text] [Related]
5. Target of rapamcyin (TOR)-based therapeutics for cardiomyopathy: insights from zebrafish genetics.
Ding Y; Sun X; Redfield M; Kushwaha S; Xu X
Cell Cycle; 2012 Feb; 11(3):428-9. PubMed ID: 22262179
[No Abstract] [Full Text] [Related]
6. Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin passes the torch: a new generation of mTOR inhibitors.
Benjamin D; Colombi M; Moroni C; Hall MN
Nat Rev Drug Discov; 2011 Oct; 10(11):868-80. PubMed ID: 22037041
[TBL] [Abstract][Full Text] [Related]
8. mTOR signaling pathway and mTOR inhibitors in cancer therapy.
Gomez-Pinillos A; Ferrari AC
Hematol Oncol Clin North Am; 2012 Jun; 26(3):483-505, vii. PubMed ID: 22520976
[TBL] [Abstract][Full Text] [Related]
9. Targeting mTOR signaling pathway in ovarian cancer.
Mabuchi S; Hisamatsu T; Kimura T
Curr Med Chem; 2011; 18(19):2960-8. PubMed ID: 21651485
[TBL] [Abstract][Full Text] [Related]
10. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.
Zhang YJ; Duan Y; Zheng XF
Drug Discov Today; 2011 Apr; 16(7-8):325-31. PubMed ID: 21333749
[TBL] [Abstract][Full Text] [Related]
11. mTOR, glycotoxins and the parallel universe.
Green AS
Aging (Albany NY); 2018 Dec; 10(12):3654-3656. PubMed ID: 30540565
[No Abstract] [Full Text] [Related]
12. Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.
Marshall G; Howard Z; Dry J; Fenton S; Heathcote D; Gray N; Keen H; Logie A; Holt S; Smith P; Guichard SM
Biochem Soc Trans; 2011 Apr; 39(2):456-9. PubMed ID: 21428919
[TBL] [Abstract][Full Text] [Related]
13. Current status and challenges associated with targeting mTOR for cancer therapy.
Dowling RJ; Pollak M; Sonenberg N
BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
[TBL] [Abstract][Full Text] [Related]
14. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
Tedesco Silva H
Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
[No Abstract] [Full Text] [Related]
15. mTOR inhibitors: facing new challenges ahead.
Mavrommati I; Maffucci T
Curr Med Chem; 2011; 18(18):2743-62. PubMed ID: 21649581
[TBL] [Abstract][Full Text] [Related]
16. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
17. mTOR as a therapeutic target in patients with gastric cancer.
Al-Batran SE; Ducreux M; Ohtsu A
Int J Cancer; 2012 Feb; 130(3):491-6. PubMed ID: 21898386
[TBL] [Abstract][Full Text] [Related]
18. Everolimus.
Hasskarl J
Recent Results Cancer Res; 2014; 201():373-92. PubMed ID: 24756805
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.
Vincenzi B; Napolitano A; D'Onofrio L; Frezza AM; Silletta M; Venditti O; Santini D; Tonini G
Expert Opin Investig Drugs; 2011 Dec; 20(12):1685-705. PubMed ID: 22010859
[TBL] [Abstract][Full Text] [Related]
20. Blocking the mTOR pathway: a drug discovery perspective.
Garcia-Echeverria C
Biochem Soc Trans; 2011 Apr; 39(2):451-5. PubMed ID: 21428918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
